tiprankstipranks
Trending News
More News >
Innoviva Inc (INVA)
NASDAQ:INVA
Advertisement

Innoviva (INVA) AI Stock Analysis

Compare
315 Followers

Top Page

INVA

Innoviva

(NASDAQ:INVA)

Select Model
Select Model
Select Model
Neutral 55 (OpenAI - 4o)
Rating:55Neutral
Price Target:
$19.50
▲(10.42% Upside)
Innoviva's overall stock score is primarily influenced by its mixed financial performance and bearish technical indicators. The strong cash flow and profitability metrics are offset by declining revenue growth and operational efficiency challenges. The technical analysis indicates a bearish trend, and the high P/E ratio suggests potential overvaluation. The absence of earnings call insights and corporate events means these factors do not influence the score.
Positive Factors
Cash Flow Health
Strong cash flow health supports operational and strategic initiatives, providing financial flexibility and resilience.
Profitability
High profitability margins indicate efficient cost management and pricing power, supporting long-term financial stability.
Stable Balance Sheet
A stable balance sheet with moderate leverage provides a solid foundation for future growth and financial stability.
Negative Factors
Declining Revenue Growth
Declining revenue growth may hinder the company's ability to expand market share and achieve long-term sales targets.
Operational Efficiency Challenges
Decreasing operational efficiency could impact profitability and competitiveness, necessitating improvements in cost management.
Low Return on Equity
Low ROE suggests declining shareholder returns, which may affect investor confidence and long-term investment appeal.

Innoviva (INVA) vs. SPDR S&P 500 ETF (SPY)

Innoviva Business Overview & Revenue Model

Company DescriptionInnoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
How the Company Makes MoneyInnoviva generates revenue primarily through royalties from its partnered products, particularly those developed in collaboration with other pharmaceutical companies. A significant portion of their earnings comes from royalties on sales of the drug Trelegy Ellipta, a combination therapy for COPD, which is marketed by GlaxoSmithKline (GSK). Additionally, Innoviva may engage in milestone payments from its partners based on the achievement of certain development and sales targets. The company also explores other revenue opportunities through licensing agreements and collaborations that enhance its product offerings and expand its market reach.

Innoviva Financial Statement Overview

Summary
Innoviva presents a mixed financial picture. While profitability and cash flow metrics are strong, the declining revenue growth and reduced return on equity highlight potential challenges. The balance sheet remains stable with moderate leverage, providing a solid foundation for future growth. The company should focus on revitalizing revenue growth and improving operational efficiency to enhance overall financial performance.
Income Statement
65
Positive
Innoviva's income statement shows a mixed performance. The TTM (Trailing-Twelve-Months) data reveals a decline in revenue growth rate, indicating potential challenges in maintaining sales momentum. However, the company maintains a healthy gross profit margin of 88.34% and a net profit margin of 10.44%, showcasing strong profitability. The EBIT and EBITDA margins are also positive, though they have decreased compared to previous years, suggesting some pressure on operational efficiency.
Balance Sheet
70
Positive
The balance sheet reflects a stable financial position with a debt-to-equity ratio of 0.63, indicating moderate leverage. The return on equity (ROE) is 5.68%, which is relatively low compared to previous years, suggesting a decline in shareholder returns. The equity ratio stands at 53.58%, highlighting a solid equity base relative to total assets. Overall, the balance sheet suggests stability but with room for improvement in profitability.
Cash Flow
75
Positive
Innoviva's cash flow statement is strong, with a positive free cash flow growth rate of 18.1% in the TTM period. The operating cash flow to net income ratio is 0.81, indicating efficient cash generation relative to net income. The free cash flow to net income ratio is high at 0.98, reflecting effective cash management. These metrics suggest robust cash flow health, supporting the company's operational and strategic initiatives.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue370.23M358.71M310.46M331.34M391.87M336.79M
Gross Profit327.08M322.11M261.06M317.55M378.03M335.01M
EBITDA111.53M99.45M248.96M322.25M478.18M386.42M
Net Income38.65M23.39M179.72M213.92M368.84M224.40M
Balance Sheet
Total Assets1.33B1.30B1.24B1.23B926.39M999.57M
Cash, Cash Equivalents and Short-Term Investments497.73M412.50M193.51M291.05M201.53M246.49M
Total Debt450.90M451.10M449.08M637.88M394.65M385.52M
Total Liabilities618.75M609.90M568.55M665.71M400.46M391.73M
Stockholders Equity714.82M691.16M674.96M565.79M414.74M539.91M
Cash Flow
Free Cash Flow196.34M188.42M140.65M201.66M362.51M313.10M
Operating Cash Flow200.62M188.69M141.06M201.73M363.81M313.11M
Investing Cash Flow-22.30M-63.79M-66.76M-56.63M43.72M-314.94M
Financing Cash Flow2.21M-13.45M-171.84M-55.57M-452.50M-29.79M

Innoviva Technical Analysis

Technical Analysis Sentiment
Negative
Last Price17.66
Price Trends
50DMA
19.46
Negative
100DMA
19.67
Negative
200DMA
18.83
Negative
Market Momentum
MACD
-0.45
Positive
RSI
29.71
Positive
STOCH
19.38
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INVA, the sentiment is Negative. The current price of 17.66 is below the 20-day moving average (MA) of 19.24, below the 50-day MA of 19.46, and below the 200-day MA of 18.83, indicating a bearish trend. The MACD of -0.45 indicates Positive momentum. The RSI at 29.71 is Positive, neither overbought nor oversold. The STOCH value of 19.38 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INVA.

Innoviva Risk Analysis

Innoviva disclosed 73 risk factors in its most recent earnings report. Innoviva reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Innoviva Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
74
Outperform
$1.21B5.9433.02%799.36%
55
Neutral
$1.11B53.215.60%11.54%-72.73%
55
Neutral
$1.34B-39.11165.76%35.62%49.58%
46
Neutral
$1.38B-25.4579.90%
45
Neutral
$1.23B-13.936.66%
44
Neutral
$1.32B-11.59
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
INVA
Innoviva
17.66
-1.84
-9.44%
XERS
Xeris Pharmaceuticals
8.31
5.33
178.86%
CVAC
CureVac
5.39
2.43
82.09%
TRML
Tourmaline Bio
47.87
21.62
82.36%
LENZ
LENZ Therapeutics
48.32
25.84
114.95%
RAPP
Rapport Therapeutics, Inc.
28.54
10.20
55.62%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 20, 2025